Pharmacoeconomic review report : (Lundbeck Canada Inc. and Otsuka Canada Pharmaceutical Inc.) : indication: treatment of schizophrenia in adults. Brexpiprazole (Rexulti) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Language:

English

Subjects (All):

Schizophrenia.

Social psychiatry.

Physical Description:

1 online resource (15 pages)

Place of Publication:

[Ottawa Ontario] : Canadian Agency for Drugs and Technologies in Health, 2017.

Summary:

Brexpiprazole (Rexulti) is an oral atypical antipsychotic (AAP) drug indicated for the treatment of schizophrenia in adults. It is available as a 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg tablet at a flat price of .50 per tablet, or .50 per day at the recommended dosage of 2 mg to 4 mg daily. According to the product monograph for brexpiprazole, a starting dosage of 1 mg daily is recommended on days 1 to 4, followed by titration to a 2 mg daily dosage on days 5 to 7; daily dose may be increased to 4 mg on day 8 according to the patient's clinical response and tolerability. The maximum recommended daily dose is 4 mg for most patients. The manufacturer is seeking reimbursement of brexpiprazole for the treatment of schizophrenia in adults, as per the Health Canada- approved indication.

Contents:

Abbreviations

Summary

Background

Summary of the Economic Analysis Submitted by the Manufacturer

Key Limitations

Issues for Consideration

Results/Conclusions

Cost Comparison Table

Appendix 1. Price Reduction Analysis

Appendix 2. Reviewer Worksheets

References.

Notes:

Description based on publisher supplied metadata and other sources.